Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer

Current Opinion in Oncology

Volumn 29, Issue 2, 2017, Pages 97-104

  Remon, Jordi ^a   Besse, Benjamin ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

first line; immune checkpoint inhibitors; immunotherapy; non small cell lung cancer; programmed death 1; programmed death ligand 1

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE QUALITY; HUMAN; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOLOGY; LUNG NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; CARCINOMA, NON-SMALL-CELL LUNG; CTLA-4 ANTIGEN; HUMANS; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85008336788     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000351     Document Type: Review

References (56)

1. Brahmer JR. Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin Oncol 2014; 41:126-132.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
3. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373:123-135.
4. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373:1627-1639.
5. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced nonsmall-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387:1540-1550.
6. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2016. [Epub ahead of print].
7. Fehrenbacher L, Spira A, Ballinger M, et al. POPLAR Study Group, Atezolizumab versus docetaxel for patients with previously treated nonsmall-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; 387:1837-1846.
8. GarassinoM, Rizvi N, Besse B, et al. Atezolizumab as 1L therapy for advanced NSCLC in PD-L1-selected patients: updated ORR, PFS and OS data from the BIRCH study. J Thorac Oncol 2016; Abstract 4799 (n.d.).
9. Rizvi NA, Brahmer JR, Ou S-HI, et al. Antonia, Safety and clinical activity of MEDI4736, an antiprogrammed cell death-ligand 1 (PD-L1) antibody, in patients with nonsmall cell lung cancer (NSCLC). ASCO Meeting Abstracts 2015; 33:8032.
10. Gulley JL, Spigel D, Kelly K, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. ASCO Meeting Abstracts 2015; 33:8034.
11. Garon EB, Gandhi I, Rizvi N, et al. Antitumor activity of pembrolizumab and correlation with programmed death ligand (PD-L1) expression in a pooled analysis of patients with advanced nonsmall cell lung cacrcinoma. Ann Oncol 2014; 25:. v1-v41. (n.d.).
12. Hellmann MD, Creelan BC, Woo K, et al. Smoking history and response to nivolumab in aptients with advacned NSCLC. Ann Oncol 2014; 25 (Suppl 4). iv429. (n.d.).
13. Herbst RS, Soria J-C, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-567.
14. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in nonsmall cell lung cancer. Science 2015; 348:124-128.
15. Remon J, Chaput N, Planchard D. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer. Curr Opin Oncol 2016; 28:122-129.
16. Garon EB, Rizvi NA, Hui R, et al. KEYNOTE-001 Investigators, Pembrolizumab for the treatment of nonsmall-cell lung cancer. N Engl J Med 2015; 372:2018-2028.
17. Novello S, Barlesi F, Califano R, et al. Peters, ESMO Guidelines Committee, metastatic nonsmall-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27:; v1-v27.
18. Reck M, Rodríguez-Abreu D, Robinson AG, et al. KEYNOTE-024 investigators, pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375:1823-1833.
19. Socinski M. CheckMate 026: A phase 3 trial of nivolumab vs investigator?s choice of platinum based doublet chemotherapy as first-line therapy for stage IV/recurrent programmed death ligand 1 positive NSCLC. ESMO 2016.
20. Langer CJ, Gadgeel SM, Borghaei H, et al. KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, nonsquamous nonsmall-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016; 17:1497-1508.
21. Hellmann MD, Gettinger SN, Goldman JW, et al. CheckMate 012: safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. ASCO Meeting Abstracts 2016; 34:3001.
22. Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in nonsmall cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 2016; 17:299-308.
23. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016; 375:819-829.
24. Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2016; 34:2980-2987.
25. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced nonsmall-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012; 30:2055-2062.
26. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage nonsmall-cell lung cancer. J Clin Oncol 2008; 26:3543-3551.
27. Antonia SJ, Kim S-W, Spira AI, et al. Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naive patients with advanced nonsmall-cell lung cancer. ASCO Meeting Abstracts 2016; 34:9029.
28. Verschraegen CF, Chen F, Spigel DR, et al. Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression. ASCO Meeting Abstracts 2016; 34:9036.
29. Salloum RG, Smith TJ, Jensen GA, Lafata JE. Using claims-based measures to predict performance status score in patients with lung cancer. Cancer 2011; 117:1038-1048.
30. Moro-Sibilot D, Smit E, de Castro Carpeño J, et al. Nonsmall cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: analysis from the European FRAME study. Lung Cancer 2015; 90:427-432.
31. Khan SA, Pruitt SL, Xuan L, Gerber DE. Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options. JAMA Oncol 2016; 2:1507-1508.
32. Liu WM, Fowler DW, Smith P, Dalgleish AG. Pretreatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 2010; 102:115-123.
33. Peng J, Hamanishi J, Matsumura N, et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res 2015; 75:5034-5045.
34. Zhang P, Ma Y, Lv C, et al. The up-regulation of PD-L1 promotes the resistant response in nonsmall cell lung cancer patients with neo-Adjuvant chemotherapy. Cancer Sci 2016; 107:1563-1571.
35. Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2016; 34:2969-2979.
36. Kanda S, Goto K, Shiraishi H, et al. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced nonsmall-cell lung cancer: a four arms phase Ib study. Ann Oncol 2016. [Epub ahead of print]
37. Gadgeel SM, Stevenson J, Langer CJ, et al. Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. ASCO Meeting Abstracts 2016; 34:9016.
38. Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous nonsmall-cell lung cancer. J Clin Oncol 2013; 31:4349-4357.
39. Giaccone G, Camidge D, Liu S, et al. Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy in nonsmall cell lung cancer (NSCLC): a phase Ib study. J Thorac Oncol 2015; 10 (Suppl 2):247 (n.d.). [Epub ahead of print]
40. Reck M, Popat S, Reinmuth N, et al. ESMO Guidelines Working Group, Metastatic nonsmall-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Supple 3); iii27-39.
41. Herbst R, Martin-Liberal J, Calvo E, et al. Interim safety and clinical activity in patients with advanced NSCLC from a multicohort phase I study of ramucirumab plus pembrolizumab. ESMO 2016. LBA38. (n.d.).
42. Hodi FS, O?Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
43. Zatloukal P, Heo DS, Park K, et al. Randomized phase II clinical trial comparing tremelimumab (CP-675, 206) with best supportive care (BSC) following firstline platinum-based therapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC). ASCO Meeting Abstracts 2009; 27:8071.
44. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV nonsmall-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30:2046-2054.
45. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-264.
46. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells withinB16melanoma tumors. ProcNatlAcadSciUSA2010;107:4275-4280.
47. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34.
48. Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016; 17:883-895.
49. Patnaik A, Socinski MA, Gubens MA, et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced nonsmall cell lung cancer (NSCLC): KEYNOTE-021 cohort D. ASCO Meeting Abstracts 2015; 33:8011.
50. Lee CK, Man J, Lord S, et al. Brief report: Checkpoint inhibitors in metastatic EGFR mutated nonsmall-cell lung cancer-A meta-Analysis. J Thorac Oncol 2016. [Epub ahead of print]
51. Hui R, Gandhi L, Carcereny E, et al. Long-Term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab. J Clin Oncol 2016; 34:. abstract 9026 (n.d.).
52. Lin K, Cheng J, Yang T, et al. EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-(B. Biochem Biophys Res Commun 2015; 463:95-101.
53. Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3:1355-1363.
54. D?Incecco A, Andreozzi M, Ludovini V, et al. PD-1 and PD-L1 expression in molecularly selected nonsmall-cell lung cancer patients. Br J Cancer 2015; 112:95-102.
55. Rizvi NA, Chow LQM, Borghaei H, et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. ASCO Meeting Abstracts 2014; 32:8022.
56. Creelan BC, Chow LQ, Kim D-W, et al. Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 antiprogrammed cell deathligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with nonsmall-cell lung cancer (NSCLC). ASCO Meeting Abstracts 2015; 33:3047.